Skip to main content
editorial
. 2022 Sep 1;11(4):1457–1473. doi: 10.1007/s40120-022-00401-4

Fig. 1.

Fig. 1

Epitopes on the CD20 transmembrane receptor and the binding sites of ocrelizumab (OCR), rituximab (RTX), and ofatumumab (OMB) [71].

Reproduced from Klein et al. [71], with permission from Taylor & Francis Ltd. www.tandfonline.com